STOCK TITAN

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management

Enanta Pharmaceuticals, Inc. announced the appointment of Matthew P. Kowalsky as Chief Legal Officer. With over 20 years of legal experience in the life sciences industry, he will lead all legal and compliance activities for Enanta, providing strategic guidance and corporate governance oversight. Kowalsky's background includes roles at Sigilon Therapeutics, Proteon Therapeutics, Sanofi Genzyme, Cubist Pharmaceuticals, ARIAD Pharmaceuticals, and Lantheus Medical Imaging, among others. His expertise in corporate governance, public company reporting, intellectual property, financing, and business development makes him a valuable addition to Enanta's leadership team.

Enanta Pharmaceuticals, Inc. ha annunciato la nomina di Matthew P. Kowalsky come Direttore Legale. Con oltre 20 anni di esperienza nel settore delle scienze della vita, egli guiderà tutte le attività legali e di conformità per Enanta, fornendo orientamento strategico e supervisione della governance aziendale. Kowalsky ha ricoperto ruoli presso Sigilon Therapeutics, Proteon Therapeutics, Sanofi Genzyme, Cubist Pharmaceuticals, ARIAD Pharmaceuticals e Lantheus Medical Imaging, tra gli altri. La sua competenza in governance aziendale, relazioni con le pubbliche autorità, proprietà intellettuale, finanziamenti e sviluppo commerciale lo rendono un'aggiunta preziosa al team di leadership di Enanta.
Enanta Pharmaceuticals, Inc. ha anunciado el nombramiento de Matthew P. Kowalsky como Director Jurídico. Con más de 20 años de experiencia en el sector de las ciencias de la vida, liderará todas las actividades legales y de cumplimiento en Enanta, proporcionando orientación estratégica y supervisión de la gobernanza corporativa. Kowalsky ha desempeñado roles en Sigilon Therapeutics, Proteon Therapeutics, Sanofi Genzyme, Cubist Pharmaceuticals, ARIAD Pharmaceuticals y Lantheus Medical Imaging, entre otros. Su experiencia en gobernanza corporativa, informes de empresas públicas, propiedad intelectual, financiación y desarrollo empresarial lo convierte en una valiosa incorporación al equipo directivo de Enanta.
Enanta Pharmaceuticals, Inc.는 Matthew P. Kowalsky를 Chief Legal Officer로 임명했다고 발표했습니다. 생명 과학 산업에서 20년 이상의 법률 경험을 가진 그는 Enanta의 모든 법률 및 컴플라이언스 활동을 주도하며 전략적 지침과 기업 거버넌스 감독을 제공할 것입니다. Kowalsky는 Sigilon Therapeutics, Proteon Therapeutics, Sanofi Genzyme, Cubist Pharmaceuticals, ARIAD Pharmaceuticals, Lantheus Medical Imaging 등에서 역할을 수행했습니다. 그의 기업 거버넌스, 공공 회사 보고, 지적 재산권, 자금 조달 및 사업 개발에 대한 전문 지식은 그를 Enanta의 리더십 팀에 귀중한 자산으로 만듭니다.
Enanta Pharmaceuticals, Inc. a annoncé la nomination de Matthew P. Kowalsky en tant que directeur juridique. Fort de plus de 20 ans d'expérience dans le secteur des sciences de la vie, il dirigera toutes les activités juridiques et de conformité chez Enanta, fournissant des conseils stratégiques et une supervision de la gouvernance d'entreprise. Kowalsky a occupé des postes chez Sigilon Therapeutics, Proteon Therapeutics, Sanofi Genzyme, Cubist Pharmaceuticals, ARIAD Pharmaceuticals et Lantheus Medical Imaging, entre autres. Son expertise en gouvernance d'entreprise, en reporting public, en propriété intellectuelle, en financement et en développement des affaires le rend un ajout précieux à l'équipe de direction d'Enanta.
Enanta Pharmaceuticals, Inc. hat die Ernennung von Matthew P. Kowalsky zum Chief Legal Officer bekannt gegeben. Mit mehr als 20 Jahren Erfahrung im Bereich Life Sciences wird er alle rechtlichen und Compliance-Aktivitäten bei Enanta leiten und strategische Führung sowie Aufsicht über die Unternehmensführung bieten. Kowalskys Hintergrund umfasst Positionen bei Sigilon Therapeutics, Proteon Therapeutics, Sanofi Genzyme, Cubist Pharmaceuticals, ARIAD Pharmaceuticals und Lantheus Medical Imaging unter anderen. Seine Expertise in Unternehmensführung, Berichterstattung öffentlicher Unternehmen, geistigem Eigentum, Finanzierung und Geschäftsentwicklung macht ihn zu einer wertvollen Ergänzung des Führungsteams von Enanta.
Positive
  • Matthew P. Kowalsky brings over 20 years of legal experience in the life sciences industry, specializing in various disciplines including corporate governance, public company reporting, and business development.
  • Kowalsky's proven track record in handling legal matters will support Enanta's growth and mission of developing important medicines in virology and immunology, enhancing shareholder value.
  • Enanta's appointment of Kowalsky as Chief Legal Officer signifies a strategic move to strengthen the company's legal and compliance activities, providing valuable guidance and oversight.
Negative
  • None.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight.

Matthew P. Kowalsky, Chief Legal Officer, Enanta Pharmaceuticals, Inc. (Photo: Business Wire)

Matthew P. Kowalsky, Chief Legal Officer, Enanta Pharmaceuticals, Inc. (Photo: Business Wire)

“I’m pleased to welcome Matt to Enanta. The breadth of his legal expertise across a wide range of activities in the life sciences industry, including his experience with early and late-stage clinical trials, commercial products, intellectual property, business development and other corporate transactions, makes him an important addition to the Enanta leadership team as we advance toward several important catalysts this year,” commented Jay R. Luly, Ph.D., President and Chief Executive Officer at Enanta Pharmaceuticals. “In addition to his strong expertise and experience, Matt is a proven leader in life sciences, which will support our continued growth as we further our mission of developing important medicines in virology and immunology.”

“I’m proud to join a team with an established track record of success, dedicated to the discovery and development of groundbreaking small molecule drugs in areas of significant unmet medical need,” said Matthew Kowalsky. “With multiple near-term catalysts across the pipeline and a solid cash position, this is an important and transformational time for Enanta. I look forward to collaborating with the seasoned management team to support all initiatives aimed at progressing our pipeline, improving the lives of patients and their caregivers, and enhancing shareholder value.”

Mr. Kowalsky brings more than 20 years of experience handling legal matters across a range of disciplines, including corporate governance, public company reporting, intellectual property, financing, business development and M&A activities in the life sciences industry. Prior to joining Enanta, Mr. Kowalsky held legal and operational roles of increasing responsibility at Sigilon Therapeutics, Inc., until its acquisition by Eli Lilly in 2023. Most recently, he served as the Chief of Staff and Chief Legal and Administrative Officer of Sigilon, which he joined in 2019 as its General Counsel and Corporate Secretary. Prior to Sigilon, Mr. Kowalsky was Vice President of Legal and Corporate Secretary at Proteon Therapeutics, Inc. from 2016 to 2019. Previously, he served as Senior Corporate Counsel at Sanofi Genzyme, supporting business development activities, marketed products and alliances for the rare disease business. Earlier, Mr. Kowalsky held similar roles at Cubist Pharmaceuticals, Inc., ARIAD Pharmaceuticals, Inc. and Lantheus Medical Imaging, Inc., formerly Bristol-Myers Squibb Medical Imaging, Inc. Mr. Kowalsky began his legal career in the corporate and intellectual property groups of Choate, Hall & Stewart LLP. He holds a B.A. from the University of Notre Dame and a J.D. from the Notre Dame Law School. Before attending law school, he served as a surface warfare officer in the U.S. Navy.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for virology and immunology indications. Enanta’s research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus infection (HCV) and is sold by AbbVie in numerous countries under the trade names MAVYRET®(U.S.) and MAVIRET®(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit http://www.enanta.com for more information.

Media and Investors

Jennifer Viera

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

Who is the new Chief Legal Officer appointed by Enanta Pharmaceuticals?

Matthew P. Kowalsky has been appointed as the Chief Legal Officer at Enanta Pharmaceuticals.

What is Matthew P. Kowalsky's role at Enanta Pharmaceuticals?

Matthew P. Kowalsky will lead all legal and compliance activities for Enanta, providing strategic guidance and corporate governance oversight.

What is Enanta Pharmaceuticals' stock symbol?

The stock symbol for Enanta Pharmaceuticals is ENTA.

What experience does Matthew P. Kowalsky bring to Enanta Pharmaceuticals?

Matthew P. Kowalsky has over 20 years of experience handling legal matters in the life sciences industry, with expertise in corporate governance, public company reporting, and business development.

Where did Matthew P. Kowalsky work before joining Enanta Pharmaceuticals?

Before joining Enanta Pharmaceuticals, Matthew P. Kowalsky worked at Sigilon Therapeutics, Proteon Therapeutics, Sanofi Genzyme, Cubist Pharmaceuticals, ARIAD Pharmaceuticals, and Lantheus Medical Imaging, among others.

Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

ENTA Rankings

ENTA Latest News

ENTA Stock Data

342.05M
21.18M
6.09%
107.12%
13.01%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
WATERTOWN